// App-Quantinova.ai

P14.03 : Vibostolimab Plus Pembrolizumab With/Without Docetaxel vs Docetaxel in NSCLC After Platinum Chemotherapy and Immunotherapy

Researchers

Presenter

  • S. Peters

Principal Investigators

  • D.H. Lee

  • C. Schumann

  • D. Planchard

  • Q. Chen

  • S. Novello

Medical Centers

  • Gustave Roussy, Department of Medical Oncology, Thoracic Group, Villejuif, France

  • Asan Medical Center, Seoul,

  • Merck & Co., Inc., Kenilworth, NJ

  • Department of Oncology, Azienda Ospedaliero-Universitaria San Luigi Gonzaga University of Turin, Orbassano/IT

  • Klinik Für Pneumologie, Thoraxonkologie, Schlaf- Und Beatmungsmedizin, Klinikverbund Allgäu, Kempten/DE

  • Poznan University of Medical Sciences, Poznan, Poland

  • University of Lausanne, Centre Hospitalier Universitaire Vaudois, Lausanne/CH

  • Department of Oncology, Montefiore Einstein Center for Cancer Care, New York/NY/US

Locations

  • France

  • United Kingdom

  • Italy

  • United States

  • Republic of South Korea

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Brain metastasis

  • Non Small Cell Lung cancer

Biomarkers

  • P14

  • Anaplastic lymphoma Kinase

  • Proto-oncogene tyrosine-protein kinase ROS

  • Programmed death-ligand 1

  • Epidermal growth factor receptor

Drug/Treatment

  • Pembrolizumab

  • Docetaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

  • Parallel Group

Phase

  • II

Study Id's

  • NCT02964013

  • NCT04725188

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved